KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Receivables (2016 - 2024)

CRISPR Therapeutics AG's Receivables history spans 10 years, with the latest figure at $27.1 million for Q4 2024.

  • For Q4 2024, Receivables fell 86.88% year-over-year to $27.1 million; the TTM value through Dec 2024 reached $27.1 million, down 86.88%, while the annual FY2024 figure was $27.1 million, 86.88% down from the prior year.
  • Receivables for Q4 2024 was $27.1 million at CRISPR Therapeutics AG, down from $206.5 million in the prior quarter.
  • Across five years, Receivables topped out at $206.5 million in Q4 2023 and bottomed at $49000.0 in Q3 2022.
  • The 5-year median for Receivables is $10.8 million (2020), against an average of $29.0 million.
  • The largest annual shift saw Receivables tumbled 99.7% in 2021 before it surged 105960.61% in 2023.
  • A 5-year view of Receivables shows it stood at $10.8 million in 2020, then fell by 19.73% to $8.7 million in 2021, then rose by 28.66% to $11.2 million in 2022, then surged by 1743.75% to $206.5 million in 2023, then tumbled by 86.88% to $27.1 million in 2024.
  • Per Business Quant, the three most recent readings for CRSP's Receivables are $27.1 million (Q4 2024), $206.5 million (Q4 2023), and $70.0 million (Q2 2023).